- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsed and/or refractory multiple myeloma (RRMM)
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1244KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 103KB)
Daratumumab – July 2021
Daratumumab: Solution for subcutaneous injection 1,800 mg in 15 mL vial; Darzalex®
Last updated
29 October 2021